OmniAb to Participate in Two Investor Conferences in March
2024年2月20日 - 10:00PM
ビジネスワイヤ(英語)
OmniAb, Inc. (NASDAQ: OABI) today announced that
management will be participating in two upcoming investor
conferences in March.
- TD Cowen 44th Annual Healthcare Conference, March 4-6, 2024,
at the Marriott Copley Place in Boston, MA. Management will
participate in a fireside chat on Monday, March 4th at 11:10 a.m.
Eastern time and will be available for one-on-one meetings with
investors.
- Leerink Partners Global Biopharma Conference, March 11-13,
2024, at the Fontainebleau Miami Beach. Management will be
hosting one-on-one meetings with the investors on Tuesday, March
12th.
About OmniAb®
OmniAb’s discovery platform provides pharmaceutical industry
partners access to diverse antibody repertoires and high-throughput
screening technologies to enable discovery of next-generation
therapeutics. At the heart of the OmniAb platform is the Biological
Intelligence™ (BI) of our proprietary transgenic animals, including
OmniRat®, OmniChicken® and OmniMouse® that have been genetically
modified to generate antibodies with human sequences to facilitate
development of human therapeutic candidates. OmniFlic® (transgenic
rat) and OmniClic® (transgenic chicken) address industry needs for
bispecific antibody applications through a common light chain
approach, and OmniTaur™ features unique structural attributes of
cow antibodies for complex targets. OmnidAb™ is an in vivo platform
for single domain antibodies based upon a human VH scaffold that
affinity matures in a chicken host environment to provide a
functionally diverse immune repertoire unavailable from mammalian
systems. We believe the OmniAb animals comprise the most diverse
host systems available in the industry and they are optimally
leveraged through computational antigen design and immunization
methods, paired with high-throughput single B cell phenotypic
screening and mining of next-generation sequencing datasets with
custom algorithms to identify fully human antibodies with superior
performance and developability characteristics. These proprietary
technologies are joined with and leverage OmniDeep™, which is a
suite of in silico tools for therapeutic discovery and optimization
that are woven throughout OmniAb’s various technologies and
capabilities. Additionally, an established core competency focused
on ion channels and transporters further differentiates OmniAb’s
technology and creates opportunities in many emerging target
classes. OmniAb antibodies have been leveraged across modalities,
including bispecific antibodies, antibody-drug conjugates and
others.
The OmniAb suite of technologies span from BI-powered repertoire
generation to cutting-edge antibody discovery and optimization
offering a highly efficient and customizable end-to-end solution
for the growing discovery needs of the global pharmaceutical
industry.
For more information, please visit www.omniab.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240220840646/en/
OmniAb, Inc. Neha Singh, Ph.D. investors@OmniAb.com X (Twitter)
@OmniAbTech (510) 768-7760
OmniAb (NASDAQ:OABI)
過去 株価チャート
から 5 2024 まで 6 2024
OmniAb (NASDAQ:OABI)
過去 株価チャート
から 6 2023 まで 6 2024